Content Type: Article

  • EEOC Issues Guidance on DEI-Related Discrimination at Work

    EEOC Issues Guidance on DEI-Related Discrimination at Work

    ARTICLE / CLIENT ALERT

    EEOC Issues Guidance on DEI-Related Discrimination at Work

    April 4, 2025

    Read time: 5 min

    Key takeaways
    Overview

    On March 19, 2025, the US Equal Employment Opportunity Commission (“EEOC”) released two documents to inform employers and employees how civil rights laws apply to diversity, equity, and inclusion (“DEI”) policies, programs and practices in the workplace.

    A one-page technical assistance document, “What to Do If You Experience Discrimination Related to DEI at Work,” provides basic information on recognizing and addressing DEI-related discrimination. It notes “DEI policies, programs, or practices may be unlawful if they involve an employer or other covered entity taking an employment action motivated—in whole or in part—by an employee’s race, sex, or another protected characteristic.” A more detailed question-and-answer technical assistance document, “What You Should Know About DEI-Related Discrimination at Work,” serves as a roadmap on how the EEOC will apply Title VII of the Civil Rights Act of 1964 (“Title VII”) to DEI initiatives and outlines the process for filing charges of discrimination with the EEOC. It emphasizes that Title VII does not only apply to individuals who are part of a “minority group,” but applies equally to all workers. The EEOC’s position is that “there is no such thing as ‘reverse’ discrimination; there is only discrimination.”

    The release of these documents underscores the federal government’s growing scrutiny of DEI initiatives. In particular, the question-and-answer document highlights potential legal pitfalls for employers when implementing or managing DEI programs.

    EEOC’s Guidance in its Question-and-Answer Document

    In this technical assistance document, the EEOC clarifies when DEI initiatives may cross the line into unlawful discrimination under Title VII. The guidance explains that Title VII prohibits employment decisions based on race, sex or other protected characteristics — even if DEI programs are aimed at promoting diversity.

    The responses to Question 7 explain that DEI initiatives may be unlawful if they involve employment actions motivated by “protected characteristics” under Title VII, such as race or sex. Employers are prohibited from “limiting, segregating, or classifying employees or applicants based on race, sex, or other protected characteristics” in any manner which affects their status or deprives them of employment opportunities. For example, it would be unlawful to limit membership in employer-sponsored activities for employees such as clubs or groups, including limiting membership in workplace groups, such as Employee Resource Groups (“ERGs”) or other employee affinity groups.

    Further, separating employees by their protected characteristics during DEI or other workplace trainings is prohibited, even if the groups receive the same content or resources. Employers also cannot restrict or grant access to mentorship, sponsorship, internship, fellowship or networking programs, including skill-building or leadership development programs, based on these protected traits. “Employers also should ensure that employees of all backgrounds … have equal access to workplace networks.”

    The responses to Questions 10 and 11 warn that DEI training could create a hostile work environment and/or give rise to claims of harassment. The EEOC highlights court cases in which employees successfully alleged that DEI-related training was discriminatory. For example, the EEOC notes that courts have ruled in favor of plaintiffs who provided evidence that DEI programs were discriminatory “in content, application, or context.” The technical assistance documents reference that “opposition to a DEI training may constitute protected activity if the employee provides a fact-specific basis for his or her belief that the training violates Title VII.”

    Next Steps for Employers

    In light of these recent developments, all employers should evaluate their current DEI-related policies, practices and programs by conducting legally-privileged audits and risk assessments to ensure compliance with existing anti-discrimination statutes, such as Title VII. Any DEI initiative which uses race, gender or similar classification as an eligibility criterion should be particularly analyzed, including those policies, practices and programs related to recruitment, hiring, workplace affinity and culture, and promotion. Employers are still permitted to advertise that they are an equal opportunity employer and do not discriminate on the basis of any applicable legally protected characteristic. Care should be taken as well regarding language used in describing DEI initiatives on websites and in other public disclosures.

    Authored by Mark E. Brossman, Ronald E. Richman, Martin L. Schmelkin, Donna K. Lazarus, Scott A. Gold, and Danisa D. Foote.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2025 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Mark E. Brossman

    Partner

    New York – 919 Third Avenue

    Ronald E. Richman

    Partner

    New York – 919 Third Avenue

    Martin L. Schmelkin

    Partner

    New York – 919 Third Avenue

    Donna K. Lazarus

    Partner

    New York – 919 Third Avenue

    More insights

  • Federal Court Strikes Down LDT Final Rule

    Federal Court Strikes Down LDT Final Rule

    ARTICLE / CLIENT ALERT

    Federal Court Strikes Down LDT Final Rule

    April 3, 2025

    Read time: 5 min

    Key takeaways
    Overview

    On March 31, 2025, the US District Court for the Eastern District of Texas struck down the US Food and Drug Administration’s (FDA) final rule under which FDA would have started regulating most laboratory-developed tests (LDTs) as medical devices on May 6, 2025.

    In depth

    Key takeaways from the court’s ruling include the following:

    • The court struck down the LDT final rule because it exceeded FDA’s authority under the Food, Drug, and Cosmetic Act (FDCA). The court concluded FDA’s authority to regulate “devices” extends to tangible, physical products that are commercially distributed – not professional services that use such products. In addition to a detailed analysis of the FDCA text, the court offered several bases for this conclusion, including that:
      • Congress enacted separate regulatory frameworks for clinical laboratories (e.g., the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and the Social Security Act) and medical devices (the FDCA).
      • Congress refused to grant FDA explicit authority over LDTs on several occasions in the last 20 years (e.g., the VALID Act).
      • FDA did not claim jurisdiction over LDTs for several decades after Congress initially gave it authority to regulate “devices” in 1938.
      • FDA did not adequately explain how or why it had allowed thousands of clinical laboratories to operate for “decades in open and direct violation of the law.”
      • FDA did not adequately respond to plaintiff’s claim that under FDA’s line of reasoning, any medical procedure (e.g., surgery) involving the use of a device could itself be considered a device.
    • The court’s order sets aside the LDT final rule nationwide. As a result, clinical laboratories offering LDTs will not be required to comply with any of the phases of the final rule unless FDA successfully appeals the court’s ruling.
    • The ruling reinstates the LDT oversight process that has historically been in place. Laboratories wishing to develop and use LDTs for patient care purposes will need to establish performance specifications for the tests consistent with CLIA requirements and successfully complete the New York State Clinical Laboratory Evaluation Program test approval process if offering to patients in the state (as applicable). Because LDTs are considered CLIA high-complexity tests, after validating the test, laboratories must ensure that they comply with all CLIA regulations applicable to high-complexity laboratories.

    The court’s ruling offers an answer to an important (and long-standing) legal question regarding FDA’s authority to regulate LDTs under the FDCA. However, several important questions remain unanswered. For example:

    • Will the FDA appeal? Despite speculation that the Trump administration may not appeal, neither the administration nor the US Department of Health and Human Services/FDA has announced its position on a potential appeal.
    • Will the ruling affect the FDA’s enforcement posture, and if so, how? The court’s ruling is based in no small part on its conception of an LDT as a service offered by a single clinical laboratory:

    A “laboratory-developed test” is a methodology or process by which a laboratory generates biochemical, genetic, molecular, or other forms of clinical information about a patient specimen for use by the treating physician. Each laboratory uses its own unique knowledge of the protocols, performance characteristics, and means of analysis to develop such methodologies and processes. Laboratory-developed tests are offered as services. Unlike a drug or device, which is a manufactured and packaged article of commerce with user instructions, a laboratory-developed test service is a proprietary methodology performed by only the developing laboratory. That service generates information from test results and transmits that information to the ordering physician. The testing service is not sold as a kit, and the protocol is not transferred in any manner to other laboratories, hospitals, or other facilities outside the developing laboratory entity. No physical product is sold, and no article of personal property is transferred such that title passes from one party to another.

    It is unclear whether FDA would consider taking enforcement action if certain tests offered as LDTs fall outside this fairly narrow conception.

    It is also unclear how FDA might seek to change its approach to oversight of tangible items that the litigants agreed remain subject to at least some degree of FDA oversight, such as “research use only” equipment and reagents, and/or specimen collection kits.

    • How will the ruling affect FDA’s – and external stakeholders’ – willingness to consider legislative action (e.g., the VALID Act)? Congress tried and failed to pass the VALID Act on several occasions in recent years. In congressional hearings held last year, several laboratory stakeholders expressed a preference for a legislative solution to diagnostics oversight rather than FDA’s approach in the LDT final rule. Will those stakeholders continue to be open to some form of FDA oversight? Or will they now oppose such efforts in light of the court’s ruling?
    • What will happen to clinical laboratories that might voluntarily seek FDA clearance or approval for tests offered as LDTs? Several laboratories have obtained FDA authorization for proprietary tests run and offered solely at a single location. Can laboratories continue to “opt in” to FDA oversight in light of the court’s ruling?
    Authors

    Michael W. Ryan

    Partner

    Washington, DC

    James R. Ravitz

    Partner

    Washington, DC

    Paul W. Radensky , MD

    Counsel

    Washington, DC, Miami

    More insights

  • Key Considerations When Doing Deals in Emerging Markets

    Key Considerations When Doing Deals in Emerging Markets

    ARTICLE

    Key Considerations When Doing Deals in Emerging Markets

    April 2, 2025

    Read time: 2 min

    Key takeaways
    Overview

    Emerging markets are increasingly attractive candidates for investment due to higher rates of gross domestic product growth and, in many countries, emerging mass consumer classes. However, emerging-market mergers and acquisitions (M&A) deals present very different challenges than developed-market buyers are accustomed to. This guide explores some of the less obvious challenges that a buyer may face and provides some key considerations to keep in mind when doing deals in emerging markets.

    In depth
    Authors

    Sam Snider

    Partner

    Atlanta

    More insights

  • Kentucky Legislature Ends Judicial Deference To State Agencies

    Kentucky Legislature Ends Judicial Deference To State Agencies

    ARTICLE

    Kentucky Legislature Ends Judicial Deference To State Agencies

    Apr 2, 2025

    Read time: 5 min

    Key takeaways
    Overview

    In a realignment of judicial review standards, the Kentucky General Assembly overrode Governor Andy Beshear’s (D-KY) veto of Senate Bill (SB) 84, effectively abolishing judicial deference to all agency interpretations of statutes and regulations. This development marks a shift in administrative law in the Commonwealth.

    A RESPONSE TO CHEVRON AND TO KENTUCKY COURTS

    SB 84 invokes the Supreme Court of the United States’ 2024 decision in Loper Bright Enterprises v. Raimondo, which overturned the Chevron doctrine and ended judicial deference to federal agency interpretations of statutes. The bill’s preamble provides:

    In Loper Bright Enterprises v. Raimondo, 603 U.S. 369 (2024), the United States Supreme Court ruled that the federal judiciary’s deference to the interpretation of statutes by federal agencies as articulated in Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc., 467 U.S. 837 (1984), and its progeny was unlawful.

    However, SB 84 does more than align Kentucky with the new federal standard. It also repudiates the approach taken by Kentucky’s own courts. The bill notes that decisions such as Metzinger v. Kentucky Retirement Systems, 299 S.W.3d 541 (Ky. 2009), and Kentucky Occupational Safety and Health Review Commission v. Estill County Fiscal Court, 503 S.W.3d 924 (Ky. 2016), which embraced Chevron-like deference at the state level, is a practice that the legislature now declares inconsistent with the separation of powers under the Kentucky Constitution.

    KEY PROVISIONS: DE NOVO REVIEW MANDATED

    The operative language of SB 84 creates two new sections of the Kentucky Revised Statutes (KRS) and amends an existing provision by establishing a de novo standard of review for agency, including the Kentucky Department of Revenue, interpretations:

    • An administrative body shall not interpret a statute or administrative regulation with the expectation that the interpretation of the administrative body is entitled to deference from a reviewing court. (New Section of KRS Chapter 13A.)
    • The interpretation of a statute or administrative regulation by an administrative body shall not be entitled to deference from a reviewing court. (New Section of KRS Chapter 13A.)
    • A court reviewing an administrative body’s action… shall apply de novo review to the administrative body’s interpretation of statutes, administrative regulations, and other questions of law. (New Section of KRS Chapter 446.)
    • The court shall apply de novo review of the agency’s final order on questions of law. An agency’s interpretation of a statute or administrative regulation shall not be entitled to deference from a reviewing court. (Amended KRS 13B.150.)

    This means Kentucky courts must now independently review all legal interpretations made by agencies, including in tax cases before the Kentucky Board of Tax Appeals, without any presumption of correctness.

    A CONSTITUTIONAL FLASHPOINT

    Governor Beshear vetoed the bill, arguing in his veto message that it violates the separation of powers by dictating to the judiciary how it should interpret laws. Governor Beshear’s message provides that:

    Senate Bill 84 is unconstitutional by telling the judiciary what standard of review it must apply to legal cases…It prohibits courts from deferring to a state agency’s interpretation of any statute, administrative regulation, or order. It also requires courts to resolve ambiguous questions against a finding of increased agency authority. The judicial branch is the only branch with the power and duty to decide these questions.

    Republican lawmakers countered that SB 84 strengthens the judiciary’s independence. Senate leadership said in a statement that:

    SB 84 aligns Kentucky with a national legal shift that reaffirms the judiciary’s role in interpreting statutes. The bill does not weaken governance—it strengthens separation of powers by removing undue deference to regulatory agencies and restoring courts’ neutrality in legal interpretation.

    The governor’s constitutional objections should not apply to cases before the state’s Office of Claims and Appeals (which includes the Board of Tax Appeals), which the legislature itself created.

    CONSIDERATIONS FOR TAX PRACTITIONERS

    For tax practitioners, SB 84 could reshape tax litigation strategy in Kentucky. Courts reviewing Department of Revenue guidance or interpretations – whether in audits, refund claims, or administrative appeals – are no longer bound by any deference. The Department of Revenue’s legal position is now just that – a position, not a presumption. Whether Kentucky courts fully embrace this legislative mandate or chart their own course remains to be seen.

    Either way, this is a welcome development for taxpayers and practitioners who have long argued that state agencies should not have the last word on the meaning of tax statutes. By mandating de novo review, Kentucky reinforces a neutral playing field, one where legal questions are resolved by courts without institutional bias in favor of the agency.

    Other states should take note and follow suit. Just last year, Idaho, Indiana, and Nebraska passed similar amendments restoring judicial independence from executive branch interpretations of state laws. SB 84 offers a legislative blueprint for restoring judicial independence and curbing agency overreach in the tax context. As more states grapple with the implications of Loper Bright, Kentucky’s approach provides a model for how legislatures can proactively realign administrative law with core separation of powers principles.

    Authors

    Stephen P. Kranz

    Partner

    Washington, DC

    Michael J. Hilkin

    Partner

    New York – One Vanderbilt Avenue

    Mark Nebergall

    Counsel

    Washington, DC

    Jonathan C. Hague

    Associate

    Austin

    More insights
    Endnotes

  • Colorado SB 25-198 Would Expand Notice Requirements for Material Change Healthcare Transactions

    Colorado SB 25-198 Would Expand Notice Requirements for Material Change Healthcare Transactions

    ARTICLE / CLIENT ALERT

    Colorado SB 25-198 Would Expand Notice Requirements for Material Change Healthcare Transactions

    April 1, 2025

    Read time: 11 min

    Key takeaways
    Overview

    On March 5, 2025, the Colorado state legislature introduced Senate Bill (SB) 25-198, aiming to expand Colorado’s licensed hospital notice requirements for material healthcare transactions and impose notification and disclosure requirements for mergers, acquisitions, and affiliations that materially change the ownership, operations, or governance of healthcare entities, long-term care entities, and veterinary care entities. The bill, if enacted, would require parties to a material change transaction to provide the Colorado attorney general (CO AG) with certain specific information related to the transaction and would expand the CO AG’s review and enforcement powers. The bill has been referred to the Committee on Health and Social Services.

    Key Takeaways

    If SB 25-198 is passed:

    • Parties to a proposed material change transaction must provide the CO AG with at least 60 days’ prior notice.
    • Entities with average annual revenues of $80 million or more would be subject to extensive reporting obligations. Entities with less than $80 million and less than $30 million in annual revenues, respectively, would be subject to reduced reporting obligations.
    • The CO AG would be empowered to assess proposed material change transactions for impact on public interest and to condition, enjoin, or unwind such transactions.
    • Certain reporting obligations may continue in effect for five years following closing.
    In depth

    Background

    Under current Colorado law, parties to certain healthcare mergers, acquisitions, affiliations, and other transactions involving hospitals must provide the CO AG with 60 days’ notice prior to closing. The CO AG has the power to review the transaction and, for transactions involving both for-profit and nonprofit entities, challenge the proposed transaction in court if it is not in the public interest.

    SB 25-198: Proposed Notice Requirements

    SB 25-198 would expand the 60 days’ prior notice for hospital transactions to any material change transaction involving healthcare entities, long-term care entities, veterinary care entities, or related entities, including management services organizations. The bill provides an extensive list of information required to be included in the notice based on the average annual revenues of the entities involved in or resulting from the proposed material change transaction.

    The parties also would have to provide subsequent notice to the CO AG of any alterations or modifications following the submission of the notice, including new copies of any documents or information subject to the alteration or modification. The CO AG may waive any of the disclosure requirements.

    For at least five years after the effective date of material change transaction, the parties would have to provide the CO AG with annual reports meeting specified requirements regarding any additional material change transactions, any change in charitable purpose of any assets, and the activities to satisfy any conditions agreed upon, where applicable. These annual reports would be published on the CO AG website and would have to be published on the websites of the involved parties.

    Material Change Transactions Involving Entities With Average Annual Revenues of $80 Million or More

    For material change transactions that involve or would result in an entity with an average annual revenue of at least $80 million (which appears to be inclusive of out-of-state revenues), the notice would require the most extensive disclosures, including the following information:

    • The names, headquarters business addresses, and websites of the parties; the ultimate parent entities of the parties; and any brokers, experts, or consultants used to facilitate or evaluate the transaction.
    • The leadership of the entities involved in the transaction, including all board members, managing partners, member managers, and officers.
    • The services and attributed revenue of each entity by location and type of service.
    • The current and proposed relationships between the entities and the affected care or service providers, and the locations of and services provided by such providers.
    • The current and proposed contractual relationships between the entities and insurers or third-party administrators.
    • The agreement or agreements of the transaction, any related agreements, and all related consideration.
    • The markets in which the entities expect the transaction to produce synergies or other competitive advantages, and any plans to close facilities, reduce workforce, or reduce or eliminate services.
    • A brief description of each material change transaction involving one or more of the parties in the five years immediately preceding the notice.
    • Any expert or consultant reports evaluating the transaction within the three years immediately preceding the notice.
    • Audited and unaudited financial statements and tax filings from all parties to the transaction for the preceding five fiscal years.
    • A certification that the parties will make a notice of the transaction available on a public website within seven days of notifying the CO AG.

    Any nonprofit entities involved in a material change transaction must also include an explanation of how the transaction is in the public interest and any changes to the entity’s charitable purpose resulting from the transaction. Nonprofit entities also must disclose each declarant’s compensation and benefits related to the transaction for the three years following closing along with a disclosure of any conflicts of interest.

    Material Change Transactions Involving Entities With Average Annual Revenues of at Least $30 Million and Less Than $80 Million

    For material change transactions that involve or would result in an entity with an average annual revenue of at least $30 million but less than $80 million, the notice would require disclosures that are less extensive than those noted above but still significant, including the following information:

    • The names, headquarters business addresses, and websites of the parties and the ultimate parent entities of the parties.
    • The leadership of the entities involved in the transaction, including all board members, managing partners, member managers, and officers.
    • The services and attributed revenue of each entity by location and type of service.
    • The current and proposed contractual relationships between the entities and insurers or third-party administrators.
    • The agreement or agreements that give rise to the transaction and any related agreements.
    • The markets in which the entities expect the transaction to produce synergies or other competitive advantages, and any plans to close facilities, reduce workforce, or reduce or eliminate services.
    • A brief description of the nature and purpose of the proposed transaction, including the number of individual providers affected.
    • A brief description of the nature and purpose of each material change transaction involving one or more of the parties in the five years immediately preceding the notice.
    • A certification that the parties will make a notice of the transaction available on a public website within seven days of notifying the CO AG, or a certification that no involved parties maintain a public website.
    • The anticipated effective date of the transaction.

    Material Change Transactions Involving Entities With Average Annual Revenues of Less Than $30 Million

    For material change transactions that involve or would result in an entity with an average annual revenue of less than $30 million, the notice would require basic disclosures, including the following information:

    • The names, headquarters business addresses, and websites of the parties involved in the transaction.
    • The names and contact information of all owners, directors, and officers of all parties to the transaction.
    • Identification of all locations where healthcare services, long-term care services, or veterinary services are currently provided by each party, and the type of services provided at each location.
    • A brief description of the nature and purpose of the proposed transaction, including the number of individual providers affected.
    • A brief description of the nature and purpose of each material change transaction involving one or more of the parties in the five years immediately preceding the notice.
    • A certification that the parties will make a notice of the transaction available on a public website within seven days of notifying the CO AG, or a certification that no involved parties maintain a public website.
    • The anticipated effective date of the transaction.

    CO AG Review and Assessment

    Upon submission of notice, the CO AG may review the proposed material change transaction and issue an assessment. The parties would not be permitted to close on the material change transaction until one of the following occurred:

    • The CO AG issues a statement that no formal assessment or review is necessary, or that the proposed transaction is not a material change transaction.
    • The CO AG issues an assessment that the proposed material change transaction is not likely to be contrary to the public interest.
    • A court affirms the CO AG’s assessment that the proposed material change transaction is not likely to be contrary to the public interest.
    • A court finds that the proposed material change transaction is not likely to be contrary to the public interest.
    • The CO AG does not issue a response within 90 days of notice.
    • The CO AG notifies the parties that more time is required to review the proposed material change transaction and does not issue a response within 45 days of such notice.

    The CO AG also may issue an assessment subject to the parties’ agreement to certain conditions that the CO AG deems necessary to prevent harm to the public interest.

    The parties may not close a proposed material change transaction if the CO AG determines that it is against the public interest.

    Parties may contest any assessment by the CO AG that the proposed material change transaction is contrary to public interest by petitioning the district court of the city and county of Denver within 35 days of the assessment.

    Enforcement

    Following receipt of notice, the CO AG may require additional information, statements, or documents reasonably deemed necessary and issue subpoenas. For failures to respond to such CO AG requests, the CO AG may request that a district court require such information, assess civil penalties of up to $5,000, or grant any other relief as may be necessary to obtain compliance.

    Any information received by the CO AG under the notice requirement may be shared with government agencies to assist with ongoing investigations where the agencies execute a confidentiality agreement stating that such information will remain confidential and not be admitted as evidence in a criminal prosecution against the party producing such information. The CO AG may convert any notice assessment into an antitrust investigation at any time.

    Any violations of the notice requirements would be subject to $200 fines for each day in violation, and any material change transaction for which no notice was provided may be enjoined or unwound by the CO AG.

    Key Definitions

    • “Acquisition” means an agreement, arrangement, or activity which results in an entity acquiring the ownership or control of another entity, either directly or indirectly, including:
      • Any acquisition of 30% or more of voting securities or noncorporate interests, including assets, capital, stock, membership interests, or equity interests; or
      • Written or oral arrangements that include the sale of any amount of voting securities or noncorporate interests that alters voting control of, responsibility for, or control of the governing body of an entity.
    • “Contracting affiliation” means a relationship between two or more entities that permits the entities to negotiate jointly, or for one entity to negotiate on behalf of the other entity, with insurers or third-party administrators over rates for healthcare services, long-term care services, or veterinary services. It does not include arrangements among entities under common ownership.
    • “Healthcare entity” means any entity, whether incorporated or not, that provides healthcare services.
    • “Healthcare services” means services relating to the prevention, cure, or treatment of an illness, injury, condition, or disease, including medical, surgical, chiropractic, hospital, optometric, podiatric, dental, pharmaceutical, ambulance, mental health, substance use disorder, therapeutic, preventive, diagnostic, curative, rehabilitative, palliative, and custodial services.
    • “Long-term care entity” means any entity that provides long-term care services.
    • “Long-term care services” means the services and supports used by members of all ages with functional limitations and chronic illnesses who need assistance to perform routine daily activities.
    • “Material change transaction” means a merger, acquisition, or contracting affiliation involving one or more of the following entities and includes any series of transactions taking place in any five-year period that in the aggregate result in the transfer of ownership or control of 50% or more of an entity’s assets:
      • Healthcare entities, long-term care entities, or veterinary care entities.
      • Entities organized or controlled by such entities.
      • Entities that own, manage, or exercise control over such entities.
      • Entities that represent or act on behalf of such entities in contracting with insurers or third-party administrators.
    • “Merger” means a consolidation of two or more organizations, including two or more organizations joining through a common parent organization, or two or more organizations forming a new organization.
    • “Third-party administrator” means an entity that administers payments for healthcare services on behalf of a client in exchange for an administrative fee.
    • “Veterinary care entity” means any entity that provides veterinary services.
    • “Veterinary services” means services provided by a veterinary professional.

    Analysis

    SB 25-198 continues the nationwide trend toward increased regulation of healthcare transactions. For example, a bill was recently introduced in the Illinois state legislature proposing restrictions on healthcare transactions involving private equity groups and hedge funds. (For a more detailed review of the Illinois bill, read our On the Subject “SB 1998 Would Add Consent Requirement for Certain Transactions.”)

    If passed, SB 25-198 would significantly delay future transactions involving healthcare entities in Colorado.

    The bill is currently referred to the Health and Social Services Committee. McDermott will continue to monitor the bill’s progression through the state legislature and provide updates.

    Authors

    Larry C. Guess

    Partner

    Chicago

    Patrick Zanayed

    Partner

    Chicago

    Joel C. Rush

    Partner

    Washington, DC

    Jae Hyun Lee

    Associate

    New York – One Vanderbilt Avenue

    More insights

  • Labor Law Manual

    Labor Law Manual

    ARTICLE

    Labor Law Manual

    2025

    Read time: 2 min

    Key takeaways
    Overview

    Hon.-Prof. Dr. Henrik Holzapfel has contributed as an author to the new edition of Tschöpe. In this manual, he provides insights into current developments on the subject of work product rights, including employee inventions.

    In depth
    Authors
    More insights

  • CPPA Releases Updates to Proposed CCPA Regulations

    CPPA Releases Updates to Proposed CCPA Regulations

    ARTICLE / CLIENT ALERT

    CPPA Releases Updates to Proposed CCPA Regulations

    March 28, 2025

    Read time: 6 min

    Key takeaways
    Overview

    In advance of its April 4, 2025, board meeting, the California Privacy Protection Agency (CPPA) released a discussion draft of revisions to its proposed California Consumer Privacy Act (CCPA) regulations. These revisions pertain to cybersecurity audits, risk assessments, automated decision-making technology (ADMT), serving to update the existing CCPA proposed regulations. Our prior summaries addressed the broad reach of these proposed regulations.

    The draft revisions, which follow a public comment period that saw significant activity, are fairly modest, with a few notable exceptions discussed below.

    It remains unclear whether the CPPA will consider the proposed revisions significant enough to require another 45-day public comment period, or whether the CPPA will attempt to limit the next comment period to 15 days or even decline to allow a comment period at all. In short, the outcome of the April 4, 2025, board meeting could significantly impact whether the proposed CCPA regulations come into effect in Q2 or later this year. Regardless, the draft revisions demonstrate that the CPPA is moving full speed ahead with the proposed regulations, despite opposition from California businesses and even the California legislature.

    For companies subject to the CCPA, this means it is time to begin preparing for the new regulations, which impose substantial new obligations.

    In depth

    Key Revisions

    Definitions

    The headline here is that, during their April board meeting, the CPPA will be considering a change to the definition of ADMT – a much-maligned definition in the proposed regulations. The CPPA staff has put forward three potential definitions, which are not yet reflected in the revisions:

    Source: https://cppa.ca.gov/meetings/materials/20250404_item6_presentation.pdf

    Related to the definition of ADMT, the CPPA will also consider the definition of “significant decision,” another definition that drew significant criticism for its breadth in the proposed regulations.

    Another notable change is that, if the proposed revisions are accepted, sensitive data would include a consumer’s neural data. This is defined as information generated by measuring the activity of a consumer’s central or peripheral nervous system, which cannot be inferred from nonneural information. This mirrors the neural data protections that Colorado introduced in 2024.

    Otherwise, the definitions in the proposed regulations remain largely the same as the November 22, 2024, version, with some modest tweaks. For example, physical or biological identifiers are now limited to characteristics that are used or can be used to identify a person.

    Behavioral Advertising

    One of the most scrutinized parts of the CPPA proposed regulations were the provisions that arguably would have extended opt-out rights to first-party digital advertising. That, obviously, would run counter to the statutory regime in the CCPA, which granted opt-out rights only for cross-context advertising (i.e., advertising based on information obtained about a user from other websites). At the April board meeting, the CPPA will consider removing “behavioral advertising” from the risk assessment and ADMT requirements.

    Cybersecurity Audits

    Rather than requiring businesses to conduct a cybersecurity audit within 24 months of the regulations’ effective date, the revised regulations would require businesses to perform audits by January 1, 2028, if their processing of personal information presents a significant risk to consumers’ security prior to the effective date of the regulations. If the processing does not present a significant risk to consumers’ security until after the effective date of the regulations, businesses will have until January 1, 2029.

    Under the revisions, audit documents will have to be retained by both the business and the auditor for a minimum of five years after each audit’s completion. Significantly, the purpose of cybersecurity audits under the revisions would no longer be to assess the effectiveness of each businesses various components, but instead to document that effectiveness. Another proposed revision is that if relying on other audits to satisfy their obligations under the CCPA, businesses would no longer need to explain how those other audits, assessment, or evaluations meet the requirements set forth by the CPPA.

    Privacy Risk Assessments

    A relief to most businesses is that the proposed revisions would no longer require businesses to “immediately” update a risk assessment whenever there is a material change relating to the processing activities. Instead, businesses would have to update their risk assessments as soon as “feasibly” possible, but no later than 45 calendar days from the date of the material change.

    ADMT

    In addition to the potentially significant definitional and scope changes to ADMT described above, the draft revisions would reduce the kinds of evaluations that businesses would have to undertake when using ADMT. For example, the draft revisions strike the prior requirements that a business: (1) identify the source of information, (2) explain how information is useful to certain tasks or, (3) identify how errors in the data would be measured and limited.

    During the April board meeting, the CPPA will also discuss potential changes to the “training” threshold for ADMT assessments, as well as profiling rules when ADMT is used for work or educational purposes.

    Virtual Reality and Smart Devices

    The proposed revisions would permit businesses offering virtual reality or smart devices to notify consumers “at the time” of a consumer encounter, rather than when a consumer engages with a particular device.

    Consumer Rights and Protections

    The draft revisions would no longer require businesses to inform consumers that the consumer could file a complaint with the agency and the attorney general and provide links to the complaint forms on their respective websites. Additionally, the requirement that a business annotate data that a consumer disputes the accuracy of has been removed.

    What Comes Next?

    The CCPA board will continue to discuss these and any other revisions to the proposed regulations at an April 4, 2025, board meeting. At the meeting, it is possible that the CPPA advances the revisions, in which case we anticipate one more round of public comments – either 45 or 15 days. Thereafter, we anticipate that the CPPA will seek to finalize the proposed regulations, meaning that they will come into effect later this year. That is why now is the time for businesses subject to the CCPA to begin planning for the new regulatory requirements.

    If you are interested in commenting on the proposed regulations or have any questions, please contact your regular McDermott lawyer or one of the authors of this article.

    Authors

    Jonathan Ende

    Partner

    Washington, DC

    David P. Saunders

    Partner

    Chicago

    Katelyn N. Ringrose

    Associate

    Washington, DC

    More insights

  • Reproductive Health Under the Trump Administration So Far: What’s New and What’s Next

    Reproductive Health Under the Trump Administration So Far: What’s New and What’s Next

    CLIENT ALERT / US POLICY

    Reproductive Health Under the Trump Administration So Far: What’s New and What’s Next

    March 27, 2025

    Read time: 11 min

    Key takeaways
    Overview

    Over the past two months, the second Trump administration has shifted federal policies and priorities regarding abortion, in vitro fertilization (IVF), contraception, and other reproductive-health-related matters – and it is expected to continue to do so. In addition to the federal policy agenda, many developments related to reproductive health likely will continue to occur at the state level. The Dobbs decision shifted policymaking in these areas toward the states, and lawmakers and advocates have expressed their intentions to either adhere to or protect against the new administration’s policies and agenda items. This article discusses some of the major recent trends in women’s health and reproductive health, and what is likely to come next under the new administration.

    In depth

    The Trump Administration Will Continue to Weaken Biden-Era Policies That Protect Reproductive Health

    The Hyde Amendment

    During its first month, the second Trump administration signed several executive orders (EOs) and otherwise signaled its approach to certain reproductive health measures that were previously in place. For instance, in the first week of his presidency, US President Donald Trump signed an EO entitled “Enforcing the Hyde Amendment,” which called for an end to federal funding for elective abortions and revoked two previous EOs that permitted such funding. The EO charged the Office of Management and Budget with providing guidance around implementing the mandate. While the EO was not a surprise, it referred to the Hyde Amendment and “similar laws,” leaving some ambiguity in its scope and the way in which it will be implemented in practice (e.g., it could be used to target federal funds for abortion and perhaps related services by other federal agencies, such as the US Departments of Defense, Justice, and State). In response to this EO, federal agencies could revoke Biden-era policies and reinstate or expand upon Trump administrative policies. Such efforts may include recission of Biden-era regulations that authorized travel for reproductive-health-related needs for servicemembers and their families and permitted abortion services through the US Department of Veterans Affairs.

    The Comstock Act

    Although we have not seen activity in this respect to date, the new administration will likely rescind the Comstock Act Memo, which was published by the US Department of Justice (DOJ) Office of Legal Counsel. This memo was issued in December 2022 by the Biden administration following the Dobbs decision. The Comstock Act is a federal criminal statute enacted in 1873 that prohibits interstate mailing of obscene writings and any “article or thing designed, adapted, or intended for producing abortion.” Violations of the Comstock Act are subject to fines or imprisonment. The Comstock Act Memo sets forth the opinion of the DOJ Office of Legal Counsel that the Comstock Act does not prohibit mailing abortion-inducing medication unless the sender explicitly intends for it to be used unlawfully. If the new administration revokes this memo or attempts to apply the Comstock Act to the mailing of abortion-inducing medication (and, perhaps, any abortion-inducing implements, which could have even wider-reaching implications) regardless of intent, it could become very difficult for patients to obtain abortion-inducing medication. Such actions also could lead to complications related to the provision of such medications via the mail (and potentially in person, depending on the attempted interpretation). At the time of publication, the DOJ website still included the Comstock Act Memo, noting that 18 U.S.C. § 1461 does not prohibit the mailing of abortion-inducing medication when the sender does not intend for the recipient to use the drugs unlawfully.

    The 2024 HIPAA Final Rule on Access to Reproductive Health Records and Related State Activity

    In 2024, the US Department of Health and Human Services Office for Civil Rights (OCR) published a Health Insurance Portability and Accountability Act (HIPAA) final rule to support reproductive healthcare privacy (2024 final rule). The 2024 final rule prohibits a covered entity or business associate from disclosing protected health information (PHI) for conducting an investigation into or imposing liability on any person for seeking, obtaining, providing, or facilitating reproductive healthcare where the reproductive healthcare is lawful. The 2024 final rule also prohibits disclosure of PHI to identify any person for the purpose of conducting an investigation or imposing liability. The enforcement mechanism of the 2024 final rule includes an attestation component under which a requesting party must certify that the use of the PHI is not prohibited when requested for health oversight activities, judicial or administrative proceedings, law enforcement purposes, or disclosures to coroners and medical examiners under 42 C.F.R. § 164.512. The Trump administration likely will not enforce (and may reverse) protections around reproductive health data under the 2024 final rule, which would leave a bigger gap for the states to potentially fill, as evidenced by the EO regarding enforcement of the Hyde Amendment and rollback of other Biden-era reproductive health protections.

    In response to increased scrutiny of reproductive healthcare, several states have enacted laws protecting healthcare providers, patients, and others involved in providing or receiving reproductive healthcare. Although these laws vary from state to state, they generally prohibit disclosure of data and other information related to reproductive healthcare that was lawfully obtained by a patient and provided by a healthcare provider. These laws can provide a certain level of comfort to providers that provide care to patients who travel across state lines to receive care that may be unavailable to them in their home state but is accessible and lawfully provided in another state. States that do not have such laws may seek to enact similar protections under the new administration as federal protections become less certain, particularly if the layer of protection afforded by the 2024 final rule is revoked or otherwise diminished.

    Abortion Policy Will Continue to Be Largely Dictated By States and May Expand Into New Areas of Focus

    Following the Dobbs decision, many states quickly took action to enshrine abortion protections in their laws and constitutions. Some states, such as Michigan, moved to overturn old, unenforced abortion bans on their books. Michigan further implemented laws, executive actions, and eventually a ballot measure to amend its state constitution. This trend has continued; in the November 2024 presidential election, seven states passed ballot measures to protect abortion access. However, the 2024 election also marked the first three abortion protection ballot referendums that failed to pass. Voters in South Dakota and Nebraska rejected proposed constitutional amendments, and a measure in Florida received only 57% of the vote where a 60% majority was required.

    In the years since Dobbs, new laws and court cases have largely sorted the states into two categories: states that are more protective and states that are more restrictive regarding abortion. However, the law remains unsettled in a few states, such as Georgia and Wisconsin, where pending court cases, legislative action, and gubernatorial executive action may result in different outcomes. In the 2024 election, Missouri voters passed a ballot initiative to overturn the state’s strict ban on abortion and enshrine reproductive rights in the state constitution, effectively switching the state from more restrictive to more protective. More constitutional ballot measures could come in states such as Pennsylvania, New Mexico, Virginia, and New Hampshire, where abortion rights are currently supported under state law but not enshrined in state constitutions. Abortion advocates may also focus on Iowa, South Carolina, and Florida, where recent court decisions have largely settled the law, but further litigation is possible. Restrictive states also continue to legislate additional restrictions on access to abortion.

    The majority of states can be expected to continue on their current trajectory: more protective states may continue to enact abortion protections, and more restrictive states may continue to enforce existing bans and expand prohibitions. In 2025, the focus of both protective and restrictive laws likely will continue to expand. The initial wave of post-Dobbs policymaking primarily focused on a healthcare provider’s ability to perform an abortion and a patient’s right to receive an abortion. New laws and proposals now focus on topics such as assisting others in obtaining an abortion, telehealth prescribing of abortion medications, abortion funding, abortion rights of minors, and patient data privacy.

    Trump administration policies and initiatives may impact more protective states’ abilities to provide abortion services. For instance, if the Comstock Act Memo is revoked, abortion-inducing medication may become scarce or difficult to obtain through the mail, even from a provider in a protective state to a patient in another protective state. If interpreted even more broadly by the administration, the Comstock Act could serve as a catalyst for a national abortion ban, which would almost certainly face legal challenges. While the Trump administration has not yet asked Congress for a national abortion ban, the EO that Trump signed recognizing two sexes includes personhood language regarding life beginning “at conception,” signaling that additional changes may be proposed at both the federal and state policy levels regarding fetal personhood and attendant rights. Such changes would likely result in legal challenges in federal and state courts.

    IVF Services Will Continue to Expand But May Face Friction With Abortion Prohibitions and Certain Trump Administration Priorities

    State abortion laws have somewhat solidified following Dobbs, but many laws remain unclear as to their impact on IVF providers. Many states have abortion prohibitions that predate IVF, some of which define “unborn child” from the moment of fertilization or conception. Other laws are ambiguous but contain language that arguably protects a fetus at any stage of development. Since Dobbs, state attorneys general in Arkansas, Oklahoma, Wisconsin, and other states have indicated that they will not pursue IVF providers using state abortion bans, and the Trump administration has issued an EO calling for expanded access to IVF. However, the state-level laws remain ambiguous, and there is a risk that courts may interpret such laws to apply to embryos or otherwise impact IVF access. Moreover, the EO raising the issue of fetal personhood may create friction for efforts to expand access to IVF.

    In February 2024, the Alabama Supreme Court became the first state supreme court to definitively rule that “unborn children” includes cryogenically frozen IVF embryos. The court held an IVF clinic liable under the state’s wrongful death statute after an incident in which frozen IVF embryos were destroyed. The decision initially caused several IVF providers in the state to pause services until two weeks later, when the legislature passed a specific exception to the statute for IVF providers. Even though the status quo was quickly restored, both providers and patients were significantly impacted by the period of uncertainty. In 2025 and beyond, other states could face similar test cases. In response to public support for reproductive technology, some restrictive states have proposed legislation to address, for example, the use of assistive reproductive technology and selective reduction.

    At the same time, insurance coverage for IVF and other fertility treatments has expanded and will likely continue to do so in 2025. Approximately 22 states now mandate that insurance plans provide some combination of fertility benefits, fertility preservation, and coverage for a number of IVF cycles. After July 1, 2025, all large employers in California must provide insurance coverage for fertility treatments, including coverage for unlimited embryo transfers and up to three retrievals. 2025 will also bring expanded IVF coverage options for federal employee insurance plans.

    The Right to Contraception Will Remain Vulnerable to State Lawmaking and Court Challenges

    Although the Dobbs majority opinion states that the “decision concerns the constitutional right to abortion and no other right,” and that “nothing in [the Dobbs] opinion should be understood to cast doubt on precedents that do not concern abortion,” doubt remains as to other women’s health rights. In his concurrence in Dobbs, Justice Clarence Thomas expressed interest in revisiting prior Supreme Court of the United States decisions upholding rights other than the right to abortion, such as the right to contraception upheld in Griswold v. Connecticut.

    In response to the Thomas concurrence, the federal Right to Contraception Act was introduced. The act would have enshrined a person’s statutory right to contraception and a healthcare provider’s right to provide contraception. The act passed the US House of Representatives, but the US Senate version was unable to overcome a filibuster in June 2024. Federal efforts to protect the right to contraception are unlikely to pass in the new Congress.

    Although federal action is unlikely, certain states have already protected the right to contraception under state law. Approximately 15 states and the District of Columbia currently have some form of protection for the right to contraception either by statute or under the respective state’s constitution. Under the new administration, state legislative action likely will increase with respect to the right to access contraception. Certain states with restrictive abortion policies, such as South Carolina, have proposed modifications to their abortion restrictions to explicitly protect the use of contraceptives.

    What Steps Should Stakeholder Consider Taking?

    Any company whose services touch on reproductive health or women’s health should engage in a risk assessment of their business and the ways in which the Trump administration may affect their ability to operate without complications. Although the first two months of EOs and other actions from the administration have not drastically altered the landscape for reproductive health across the country, access to reproductive and women’s health is likely to evolve over the next four years. We are closely monitoring these developments and will continue to forecast the ways in which this could impact stakeholders in the industry.

    Authors

    Stacey L. Callaghan

    Partner

    Chicago

    Evelyn S. Atwater

    Associate

    Chicago

    Dexter Golinghorst

    Associate

    Chicago

    Caroline Reignley

    Partner

    Washington, DC

    More insights

  • Key Takeaways | Tax Credit Transfer Markets: Players, Platforms & Projections

    Key Takeaways | Tax Credit Transfer Markets: Players, Platforms & Projections

    ARTICLE

    Key Takeaways | Tax Credit Transfer Markets: Players, Platforms & Projections

    March 27, 2025

    Read time: 3 min

    Key takeaways
    Overview

    On March 18, 2025, Philip Tingle joined a panel discussion during Infocast’s Solar + Wind Finance & Investment Summit titled “Tax Credit Transfer Markets: Players, Platforms & Projections” that covered market trends, pricing dynamics, insurance considerations, and the evolving sophistication of buyers in the tax credit transfer market.

    Speakers:

    • Irina Antonache, Partner, Moss Adams
    • Gareth Davies, Executive Director, Santander
    • Gabe Rubio, Principal, Sustainability & ESG Tax Co-Leader, BDO USA
    • James Stahle, Senior Managing Director, CCA Group
    • Jordan Tamchin, Executive Vice President, Tax Insurance Practice Leader, CAC Specialty
    • Philip Tingle, Partner, Global Co-Head Energy & Project Finance, McDermott Will & Emery
    In depth

    Top takeaways included:

    • Large tax credit transfer participants remain aggressive despite the recent US presidential election results, but smaller purchasers with limited tax liability may be more cautious. Most tax credit purchasers require significant protections to minimize any risk associated with the purchased credits.
    • Deal structure is the primary factor driving current pricing. Elements such as deferred payment structures, technologies, and insurance requirements can lead to better pricing.
    • Insurance continues to play a significant role in transfers. Strong insurance enhances seller creditworthiness and can make deals investment-grade for buyers. Conversely, buyers can attract sellers by reducing their insurance demands (e.g., lower dollar coverage or a reduced scope of insured risks). Additionally, some insurers are becoming more comfortable with higher step-up percentages.
    • As the transfer market matures, buyers are becoming more sophisticated. Some corporate buyers are hiring internal teams that specialize in tax credit transfers, fostering a deeper understanding of market risks.
    • Tax-equity-backed deals, rather than direct transfers, may be more attractive to buyers due to reduced administrative costs. Many investors view partnership flips as lower risk because of the additional layer of transaction diligence.
    Authors

    Philip Tingle

    Partner

    Miami

    More insights

  • Corporate Transparency Act Update: No Reporting Required for US Entities and US Persons and New Deadlines Set for Foreign Entities

    Corporate Transparency Act Update: No Reporting Required for US Entities and US Persons and New Deadlines Set for Foreign Entities

    ARTICLE / CLIENT ALERT

    Corporate Transparency Act Update: No Reporting Required for US Entities and US Persons and New Deadlines Set for Foreign Entities

    March 27, 2025

    Read time: 6 min

    Key takeaways
    Overview

    Consistent with the US Department of the Treasury’s (“Treasury”) March 2, 2025, announcement, on March 21, 2025, Treasury’s Financial Crimes Enforcement Network (“FinCEN”) issued an interim final rule (“Interim Final Rule”) narrowing the scope of reporting required under the Corporate Transparency Act and its implementing regulations (collectively, the “CTA”)[1] to exclude reporting from US entities and US persons.[2] The Interim Final Rule is subject to comments but is effective immediately upon publication in the Federal Register. Comments on the Interim Final Rule are due 60 days from its publication and it may take several more months after that for FinCEN to issue a final rule. 

    The Interim Final Rule makes four important changes to the CTA and its beneficial ownership information (“BOI”) reporting requirements:

    • Domestic Reporting Companies. Under the Interim Final Rule, entities previously defined as “domestic reporting companies” are exempt from the definition of reporting company and the CTA’s reporting requirements. That is, any entity created by the filing of a document with a secretary of state or any similar office under the law of a state or Indian tribe is no longer required to file or update BOI reports with FinCEN.
    • Foreign Reporting Companies. The definition of “reporting company” was redefined to include only those entities previously defined as “foreign reporting companies” (i.e., those entities formed under the law of foreign country and registered to do business in any state or tribal jurisdiction by filing of a document with a secretary of state or any similar office under the law of a state or Indian tribe). Foreign reporting companies continue to have BOI report filing obligations.
    • US Person Beneficial Owners. Foreign reporting companies are exempt from reporting BOI of any US persons[3] and US persons are exempt from providing BOI to foreign reporting companies.[4] Foreign reporting companies that only have US persons as beneficial owners are not required to report any beneficial owners.
    • Foreign Pooled Investment Vehicles. The Interim Final Rule also revises the special rule for foreign pooled investment vehicles to exempt them from reporting the BOI of US persons. The prior rule required foreign pooled investment vehicles that were eligible for the pooled investment vehicle exemption[5] to file a limited BOI report and report only one individual with substantial control over the entity (or if more than one, the individual who had “the greatest authority over the strategic management of the entity”) as its beneficial owner. Under the Interim Final Rule, the foreign pooled investment vehicle must now only report the BOI of one individual with substantial control that is not a US person, if any. If there are multiple individuals that are not US persons that have substantial control, the foreign pooled investment vehicle must report the BOI of the individual who has “the greatest authority over the strategic management of the entity.”

    Foreign reporting companies are required to file their initial BOI reports 30 days from publication of the Interim Final Rule or 30 days after their registration to do business in the US, whichever is later. Foreign reporting companies that have not already submitted initial BOI reports should begin preparing BOI reports for the upcoming deadline and implement procedures for submitting updated BOI reports, as required. 

    FinCEN is accepting comments on the Interim Final Rule for 60 days after it is published in the Federal Register. It will assess whether to amend the Interim Final Rule after it considers any comments submitted during the comment period and intends to issue a final rule later this year. Any clients with concerns regarding the Interim Final Rule are encouraged to submit comments to FinCEN.

    The Interim Final Rule does not address BOI already reported to FinCEN by entities that are no longer considered reporting companies. Newly exempt reporting companies (i.e., domestic reporting companies) may wish to submit a comment or seek guidance from FinCEN regarding how previously disclosed BOI will be treated in light of the changes to the CTA. We will continue to monitor for developments relating to the CTA, including any updates in pending litigation and further guidance issued by FinCEN or Treasury. 

    Authored by Melissa G.R. Goldstein, Betty Santangelo, Michael S. Didiuk, Jessica Romano, Kyle B. Hendrix and Bryson Kern.

    For assistance in navigating the CTA and Reporting Rule’s reporting requirements, please contact one of the authors or your attorney at Schulte Roth & Zabel.


    [1] For more information, please see our prior Alerts: “Corporate Transparency Act Update: Penalties Paused & Significant Reduction in Scope Expected in Forthcoming Rulemaking”; “Corporate Transparency Act Update: Reporting Requirements Reinstated With March 21 Deadline”; “Corporate Transparency Act Update: Supreme Court Stays Nationwide Injunction but Reporting Still Voluntary”; “Corporate Transparency Act Update: Preliminary Injunction Reinstated and Reporting Voluntary Once Again”; “Important Update – Corporate Transparency Act: Reporting Reinstated by Appellate Court and FinCEN Extends Deadline to Jan. 13”; “Corporate Transparency Act Update: Government Challenges Nationwide Preliminary Injunction & FinCEN Clarifies That Reports Are Voluntary”; and “Corporate Transparency Act Update: Nationwide Preliminary Injunction Enjoining Enforcement”.

    [2] FinCEN, Interim Final Rule; Request for Comments, “Beneficial Ownership Information Reporting Requirement Revision and Deadline,” 90 Fed. Reg. 13688 (Mar. 26, 2025). 

    [3] The term “United States person” means —

    (A) a citizen or resident of the United States,

    (B) a domestic partnership,

    (C) a domestic corporation,

    (D) any estate (other than a foreign estate, within the meaning of paragraph (31)), and

    (E) any trust if —

    (i) a court within the United States is able to exercise primary supervision over the administration of the trust, and

    (ii) one or more United States persons have the authority to control all substantial decisions of the trust.

    26 U.S.C. § 7701(a)(30). 

    [4] Company applicant information is still required to be provided for foreign reporting companies registered on or after Jan. 1, 2024, even if a company applicant is a US person. 

    [5] The exemption applies to pooled investment vehicles that are operated or advised by certain other exempted entities, namely, a bank, credit union, SEC-registered broker-dealer in securities, SEC-registered investment company, SEC-registered investment adviser, or venture capital fund adviser.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2025 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Melissa G.R. Goldstein

    Partner

    New York – 919 Third Avenue

    Betty Santangelo

    Counsel

    New York – 919 Third Avenue

    Kyle B. Hendrix

    Associate

    Washington, DC

    More insights